Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Crenezumab Formulations in Healthy Volunteers
NCT02427243Phase 1Completed
- Sponsor
- Genentech
- Start
- Apr 2015
- Primary completion
- Jul 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of crenezumab in Alzheimer's disease (AD) (2 arms), sponsored by Genentech. Primary endpoint: Pharmacokinetic profile of crenezumab. Started Apr 2015; status: completed.
02
Drugs
crenezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02427243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02427243.